India’s pharmaceutical sector is poised for strong revenue growth, projecting 7-9% in FY26, driven by domestic and European demand. While US market growth may moderate, operating profit margins are expected to remain resilient. Companies are increasing R&D spending and capital expenditure, focusing on speciality products. Post navigation UK interest rates: Bank of England holds interest rate at 4%; inflation lingers at 3.8% Nvidia-Intel pact: Nvidia to invest $5 billion in Intel; firms to co-develop AI infrastructure and PCs
